Session: 904. Outcomes Research: Hemoglobinopathies: Poster II
Hematology Disease Topics & Pathways:
Research, Sickle Cell Disease, Adult, Clinical Research, Health outcomes research, Health disparities research, Hemoglobinopathies, Pediatric, Patient-reported outcomes, Diseases, Young adult , Study Population, Human
Method: AYA with SCD, aged 16 to 25 years, participated in a 3-month, pilot prospective survey study. Baseline stressors were assessed using the Perceived Stress Scale and Measure of Sickle Cell Stigma. Psychosocial outcomes, including anxiety, depression, and pain interference, were measured using the PROMIS 25 and 29 within a 3-month follow-up survey. Additionally, electronic health record reviews were conducted to identify biological morbidities during the 6 months following baseline. Morbidities were quantified using a cumulative complications variable, guided by the methodology described in Blinder et al. (2013), that encompassed pulmonary, cardiac, renal, infectious, and neurological complications. Pulmonary complications (e.g., acute chest syndrome etc.) were also individually investigated, as they are the leading cause of death in SCD. Finally, participants had the option to engage in a 1-day, at-home, saliva collection between baseline and 3-month follow-up, and the cortisol awakening response was calculated for participants who completed collection.
Bivariate Pearson correlations were employed to assess the relations among continuous variables, and independent samples T-tests were used to examine differences across dichotomous variables (i.e., presence or absence of pulmonary complications). Finally, multivariate linear and logistic regressions determined unique associations when controlling for participant age and gender.
Results: Forty-nine AYA (Meanage = 19.6, 40.8% female sex) completed baseline surveys, 44 AYA completed 3-month follow-up surveys, and 33 participants completed the at-home saliva collection. Cumulative number of complications during the 6 months after baseline ranged from 0 to 2, with pulmonary complications having the most common occurrence among AYA (22.4%).
Bivariate correlations showed that perceived stress predicted psychosocial outcomes, such that stress at baseline was positively correlated with depressive symptoms (r = .55, p < .001) and pain interference (r = .30, p = .045) 3 months later. Disease stigma at baseline was correlated with greater total complications (r = .37, p = .008) and pulmonary complications (t = 3.15, p = .003) during the 6 months after baseline. Further, psychosocial factors at 3-month follow-up were also correlated with health outcomes during the 6 months after baseline. Depression was related to total complications (r = .52, p = .002), and pain interference was correlated with pulmonary complications (t = -2.75, p = .009). All bivariate associations remained significant when controlling for age and gender within multivariate regressions. Neither stress nor stigma were associated with anxiety; however, the relation between stigma at baseline and anxiety approached significance (r = .29, p = .056). Finally, exploratory analyses suggest that cortisol modifies the association between baseline stress and depressive symptoms at 3 months, such that there is a stronger association for AYA with a blunted cortisol awakening response.
Conclusion: Findings from this pilot study imply that perceived stress was prospectively related to psychosocial outcomes, whereas disease stigma predicted biological health outcomes. Additional research is needed to understand the biopsychosocial mechanisms underlying these relations, as this could inform the development of multilevel interventions to reduce the impact of stress and stigma on health outcomes for AYA with SCD during transition of care.
Disclosures: Crosby: Professional Resource Exchange: Patents & Royalties; Takeda: Membership on an entity's Board of Directors or advisory committees; Sobi: Membership on an entity's Board of Directors or advisory committees; Sanofi Genzyme: Membership on an entity's Board of Directors or advisory committees; Novo Nordisk (Forma Therapeutics): Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria. Thompson: Novartis: Research Funding; Beam Therapeutics: Consultancy, Research Funding; Editas: Consultancy, Research Funding; CRISPR/Vertex: Consultancy, Research Funding; Global Blood Therapeutics: Divested equity in a private or publicly-traded company in the past 24 months; bluebird bio: Consultancy, Research Funding.
See more of: Oral and Poster Abstracts